SHIM
SYRE icon

Stone House Investment Management’s Spyre Therapeutics SYRE Stock Holding History

Stone House Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355 Buy
+4
New +$292 ﹤0.01% 1096

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Stone House Investment Management's SYRE Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 4 shares worth $355. The stake represents ﹤0.01% of the portfolio and ranks #1096 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Stone House Investment Management held 4 shares of Spyre Therapeutics worth $355 as of Q2 2026.
  • Spyre Therapeutics was a new Stone House Investment Management position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1096 holding.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.